SCHEDULE: T. Rowe Price Amends Soleno Therapeutics Stake

T. Rowe Price Associates, Inc. has filed an amended Schedule 13G, disclosing a 6.9% beneficial ownership stake in Soleno Therapeutics Inc.

Summary

• T. Rowe Price Associates, Inc. filed an Amendment No. 1 to Schedule 13G regarding its beneficial ownership of Common Stock in Soleno Therapeutics Inc.
• The reporting person, T. Rowe Price Associates, Inc., beneficially owns an aggregate of 3,461,510 shares.
• This ownership represents 6.9% of the class of Soleno Therapeutics Inc. Common Stock.
• T. Rowe Price Associates, Inc. holds sole voting power over 3,421,107 shares and sole dispositive power over 3,454,009 shares.
• The filing date is August 14, 2025, with the event date requiring the filing being June 30, 2025.

Sentiment

Score: 5

Explanation: The filing is a routine disclosure of beneficial ownership by an investment adviser, indicating a significant but passive stake. It does not contain performance data or strategic updates to assess sentiment beyond neutrality.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance.

Industry Context

This filing indicates a significant institutional investment by T. Rowe Price Associates, Inc., a major investment adviser, in Soleno Therapeutics Inc. Such disclosures are routine for large asset managers holding passive stakes above 5% in publicly traded companies.

Stakeholder Impact

• Shareholders: Disclosure of a significant institutional holder (T. Rowe Price) may provide a degree of confidence or stability regarding the company's investor base.

Key Dates

Keywords

Soleno Therapeutics, T. Rowe Price, Schedule 13G, Beneficial Ownership, Common Stock, Investment Adviser